Gland Pharma Limited (BOM:543245)
India · Delayed Price · Currency is INR 2,504.40
-10.45 (-0.42%)
At close: Jul 31, 2026
Gland Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 64,307 | 56,165 | 56,647 | 36,246 | 44,007 | |
Revenue Growth | 14.50% | -0.85% | 56.28% | -17.64% | 27.08% |
Cost of Revenue | 24,458 | 24,621 | 25,539 | 18,595 | 22,494 |
Gross Profit | 39,849 | 31,544 | 31,108 | 17,651 | 21,513 |
Selling, General & Admin | 16,288 | 14,120 | 12,668 | 4,047 | 3,397 |
Other Operating Expenses | 7,265 | 4,878 | 5,065 | 3,271 | 3,009 |
Operating Expenses | 27,790 | 22,822 | 21,393 | 8,807 | 7,513 |
Operating Income | 12,059 | 8,721 | 9,715 | 8,844 | 14,000 |
Interest Expense | -332.79 | -373.99 | -217.9 | -62.87 | -34.02 |
Interest & Investment Income | - | 2,043 | 1,506 | 1,794 | 1,386 |
Currency Exchange Gain (Loss) | - | 2.63 | 106.05 | 571.45 | 792.05 |
Other Non Operating Income (Expenses) | 3,163 | 203.03 | 179.46 | -1.07 | -2.85 |
EBT Excluding Unusual Items | 14,889 | 10,596 | 11,288 | 11,146 | 16,142 |
Gain (Loss) on Sale of Investments | - | 12.27 | 3.48 | 28.48 | 44.89 |
Gain (Loss) on Sale of Assets | - | 0.32 | 2.49 | -0.81 | -1.78 |
Asset Writedown | - | 18.24 | - | -63.32 | - |
Other Unusual Items | -243.46 | - | - | -564.61 | - |
Pretax Income | 14,646 | 10,627 | 11,325 | 10,546 | 16,186 |
Income Tax Expense | 4,373 | 3,641 | 3,601 | 2,735 | 4,069 |
Net Income | 10,273 | 6,985 | 7,725 | 7,810 | 12,117 |
Net Income to Common | 10,273 | 6,985 | 7,725 | 7,810 | 12,117 |
Net Income Growth | 47.07% | -9.57% | -1.10% | -35.54% | 21.54% |
Shares Outstanding (Basic) | 165 | 165 | 165 | 165 | 164 |
Shares Outstanding (Diluted) | 165 | 165 | 165 | 165 | 165 |
Shares Change | 0.13% | 0.01% | 0.03% | 0.09% | 3.96% |
EPS (Basic) | 62.35 | 42.40 | 46.90 | 47.44 | 73.81 |
EPS (Diluted) | 62.28 | 42.40 | 46.89 | 47.43 | 73.64 |
EPS Growth | 46.89% | -9.58% | -1.14% | -35.59% | 16.91% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 5,406 | 5,302 | 6,069 | 1,430 | 2,794 |
Free Cash Flow Per Share | 32.77 | 32.18 | 36.84 | 8.69 | 16.98 |
Dividend Per Share | 20.000 | 18.000 | 20.000 | - | - |
Dividend Growth | 11.11% | -10.00% | - | - | - |
Gross Margin | 61.97% | 56.16% | 54.92% | 48.70% | 48.88% |
Operating Margin | 18.75% | 15.53% | 17.15% | 24.40% | 31.81% |
Profit Margin | 15.97% | 12.44% | 13.64% | 21.55% | 27.53% |
Free Cash Flow Margin | 8.41% | 9.44% | 10.71% | 3.95% | 6.35% |
EBITDA | 16,295 | 12,314 | 12,968 | 10,310 | 15,102 |
EBITDA Margin | 25.34% | 21.93% | 22.89% | 28.44% | 34.32% |
D&A For EBITDA | 4,237 | 3,593 | 3,253 | 1,466 | 1,101 |
EBIT | 12,059 | 8,721 | 9,715 | 8,844 | 14,000 |
EBIT Margin | 18.75% | 15.53% | 17.15% | 24.40% | 31.81% |
Effective Tax Rate | 29.86% | 34.27% | 31.79% | 25.94% | 25.14% |
Revenue as Reported | 67,470 | 58,301 | 58,350 | 38,651 | 46,246 |